Cassandra Pardini, PharmD

Contributing Writer https://www.rheumatologyadvisor.com

Cassandra Pardini is a freelance writer and registered pharmacist with a diverse background in drug therapy, scientific research, and the drug discovery and developmental process. She obtained her Doctor of Pharmacy degree from the Massachusetts College of Pharmacy and Health Sciences University, Master of Science degree in chemistry and chemical biology from Northeastern University, and Bachelor of Science degree in chemistry from Boston College. She currently lives in Rhode Island with her husband and 3 children.

All articles by Cassandra Pardini, PharmD

General Rheumatology

Risk for Muscle Problems Based on Statin Therapy Intensity Investigated

Cassandra Pardini, PharmD

July 2, 2021

Small increases in the risk for statin-associated muscle symptoms were observed for patients on high-intensity therapy.

General Rheumatology

Graded Administration of Second COVID-19 Vaccine Dose After Hypersensitivity

Cassandra Pardini, PharmD

April 23, 2021

Current recommendations surrounding the administration of the second COVID-19 vaccine dose to patients who experience an immediate hypersensitivity reaction to the first dose are conflicting.

General Rheumatology

Real-World Data Show Tdap Vaccination During Pregnancy Reduces Infant Pertussis Risk

Cassandra Pardini, PharmD

April 23, 2021

Tdap vaccination in the recommended 27–36-week window provides the largest benefit.

Pain Management

Case Report: Pain Medication Dose Linked to Sleepwalking

Cassandra Pardini, PharmD

April 19, 2021

The patient, who had suffered a traumatic brain injury approximately 8 months prior, presented to the emergency department complaining of increasing dizziness as well as sleepwalking frequency.

Pain Management

Pain Medication Trends Examined for Ankle Sprain Treatment in the ED

Cassandra Pardini, PharmD

April 12, 2021

Overall, opioids were found to have accounted for the majority of medications used in the ED and prescribed at discharge.

Uptravi Approved for Pulmonary Arterial Hypertension

General Rheumatology

FDA-Approved VEGFR Tyrosine Kinase Inhibitors Ranked by Cardiotoxic Potential

Cassandra Pardini, PharmD

April 1, 2021

Lenvatinib was associated with the most significant probability of producing all grades of cardiovascular injury and hypertension.

Rheumatoid Arthritis

Managing RA: Potential Interactions Possible With JAK Inhibitors

Cassandra Pardini, PharmD

February 26, 2021

Given that treatment options for RA are rapidly changing, the study authors aimed to summarize information surrounding potential drug-drug interactions with JAK inhibitors in order to help health care providers make informed decisions.

Osteoporosis

Topical Corticosteroid Use and Osteoporosis Risk Examined

Cassandra Pardini, PharmD

February 9, 2021

To determine the association between cumulative exposure of potent and very potent TCSs and osteoporosis and MOF risk, study authors utilized the Danish nationwide registries.

Fibromyalgia

Evidence Lacking for Most Fibromyalgia Therapies

Cassandra Pardini, PharmD

November 19, 2020

To assess the effectiveness of these therapies on pain reduction and quality of life improvement, study authors searched various databases for randomized or quasi-randomized clinical trials that evaluated these outcomes in fibromyalgia patients.